Quanergy to Demonstrate Groundbreaking LiDAR-Equipped Security Surveillance System at IFSEC
Quanergy Systems Inc., the leading provider of LiDAR sensors and smart sensing solutions, today announced that it will demonstrate a first-of-its-kind security solution for intruder detection and surveillance automation at IFSEC International, Europe’s premier security trade show. The demonstration will integrate Quanergy’s Q-GuardTM security technology with a PTZ (Pan-Tilt-Zoom) camera from Overview Ltd, and will take place at booth D1675 from June 20-22.
This demonstration will mark the first time Q-Guard, an intrusion detection and perimeter fencing system powered by a Quanergy LiDAR sensor, has been integrated with a PTZ camera, allowing for real-time detection, tracking, and counting using 3D point clouds and color video. The system uses LiDAR to quickly detect and classify a human intruding into a secure area, and follow that unique subject with a video security camera throughout a designated area.
"Current security systems are plagued by inefficiencies and expensive false alarms. By combining these two technologies, LiDAR and PTZ cameras, we have created a new, optimized security solution," said Dr. Louay Eldada, chief executive officer of Quanergy Systems. "With Quanergy’s Q-Guard and Overview's PTZ camera, the system can detect security breaches quickly and accurately, and will catch any intrusion. No other system on the market today provides this integrated capability.”
With a LiDAR-equipped security system, security professionals no longer need to monitor several cameras and TV screens at the same time — rather, they can be assured that the LiDAR sensor will detect intrusions into secure areas and automatically direct the camera specifically to the location in question. The system can also zoom, focus, and monitor specific zones of interest, with certain behaviors prompting it to track and record within a given space.
“We’re excited to work with Quanergy to demonstrate the integration of cutting-edge LiDAR and Overview’s advanced security cameras,” said Graham Jones, chief executive officer of Overview Ltd. “Our demonstration shows the potential of automated security services and their ability to empower businesses and individuals to more efficiently keep their property safe.”
In this integration, Quanergy will be merging its Q-Guard technology, comprising an M8 LiDAR sensor, with Overview Ltd’s Hydra Uno™ camera, which is designed for operation in harsh environments and possesses outstanding accuracy as well as ultra-smooth and rapid motion with continuous rotation in both pan and tilt. Q-Guard and Hydra can work both indoors and outdoors, and in any weather or lighting condition. The M8 LiDAR sensor provides a 360° field of view, high accuracy, fine resolution and has a maximum range exceeding 150 meters.
The Overview Hydra PTZ platform will be on display during IFSEC in the Overview booth, C700.
In addition to security, Quanergy’s LiDAR sensors have applications in more than 30 market verticals including transportation, aerial mapping, and industrial automation.
About Quanergy Systems, Inc.
Quanergy Systems, Inc. was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software, and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers the world’s leading LiDAR sensors and software for real-time capture and processing of 3D mapping data and object detection, tracking, and classification. In transportation, the data is utilized to greatly improve the accuracy and reliability of on-board driver safety systems and enhance them with perception, scenario analysis, and decision making capability for active control, as well as enable autonomous driving in the future. Quanergy’s LiDARs lead in all six key commercialization areas – price, performance, reliability, size, weight, power consumption. For more information, visit www.quanergy.com.
About Overview Ltd
Overview develops and supplies advanced camera positioning technology and specialist sensors to the OEM/ODM market. Overview develops innovative technology in order to drive commercial opportunity for their customers. Overview is a British company founded in 1985 and headquartered in South West London. Now employing approximately 45 highly skilled staff, Overview manufactures more than 75,000 camera positioning systems per year. The company has developed commercial dome cameras through to military rapid deployment three sensor systems.
Quanergy Systems Inc.
Ann Gargiulo, +1-408-245-9500
Director of Marketing Communications
Ian Cox, +44 20 8875 4065
Business Development Manager
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-30111.12.2017 09:30 | Tiedote
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or “Cami-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-301 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Hodgkin’s or non-Hodgkin’s lymphoma Dr. Steven M. Horwitz, Medical Oncologist at Memorial Sloan Kettering Cancer Center in New York City, and Principal Investigator, s
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 09:00 | Tiedote
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 08:01 | Tiedote
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials11.12.2017 01:45 | Tiedote
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 18:30 | Tiedote
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 18:30 | Tiedote
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme